Serum von Willebrand factor for early diagnosis of lung adenocarcinoma in patients with type 2 diabetes mellitus

Figure 1 Serum von Willebrand factor (ng/mL) concentrations in different groups of subjects. A: Type 2 diabetes mellitus + adenocarcinoma in situ group (n = 43); B: Type 2 diabetes mellitus group (n = 43); C: Adenocarcinoma in situ group (n = 43); D: Control group (n = 43). ^aP < 0.01. vWF: von Willebrand factor.

Figure 2 Correlation of serum von Willebrand factor with clinical indicators by multiple linear stepwise regression analysis. A: Correlation between serum von Willebrand factor and insulin-like growth factor 1; B: Serum von Willebrand factor and insulin-like growth factor binding protein 3 in the adenocarcinoma in situ group; C: Correlation between serum von Willebrand factor and insulin-like growth factor 1; D: Serum von Willebrand factor and insulin-like growth factor binding protein 3 in the type 2 diabetes mellitus + adenocarcinoma in situ group. IGF-1: Insulin-like growth factor 1; IGFBP3: Insulin-like growth factor binding protein 3; vWF: von Willebrand factor.